



NEWS RELEASE

Athersys to Host Year-End 2020 Financial Results Call

3/2/2021

Company will provide business updates during the earnings call and release investor day video segments on Company website

CLEVELAND--(BUSINESS WIRE)-- Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2020 financial results at approximately 4:00 PM Eastern Time on Thursday, March 25, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.

The Investor Day planned for February 16th will not be rescheduled. Updates that were going to be provided will be shared during the earnings call. Relevant program overview videos will be posted on the Company's website in the coming weeks. Members of the management team will host the call as follows:

Date	March 25, 2021
Time	4:30 p.m. (Eastern Time)
Live webcast registration	Webcast link
Phone registration	Call registration link

We encourage shareholders to listen using the webcast link above. If you would like to dial in using the phone to ask a question, please register for the conference call ahead of time using the call registration link above. Once

registered, you will receive an email containing the toll-free number, a direct entry passcode and a registrant ID.

A replay of the event will be available on the webcast link at www.athersys.com under the investors' section approximately two hours after the call has ended. Shareholders may also call in for on-demand listening approximately three hours after the completion of the call until 11:59 PM Eastern Time on April 5, 2021, by dialing (800) 585-8367 or (416) 621-4642 and entering the conference code **8674678**.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210302005250/en/): <https://www.businesswire.com/news/home/20210302005250/en/>

Ivor Macleod
Chief Financial Officer
Tel: (216) 431-9900
ir@athersys.com

Karen Hunady
Director of Corporate Communications and Investor Relations
Tel: (216) 431-9900
khunady@athersys.com

David Schull
Russo Partners, LLC
Tel: (212) 845-4271 or (858) 717-2310
David.schull@russopartnersllc.com

Source: Athersys, Inc.